Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 212

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Replication Gaps Underlie BRCA Deficiency and Therapy Response

Open access
Panzarino, Nicholas J., Krais, John J., Cong, Ke, Peng, Min, Mosqueda, Michelle, Nayak, Sumeet U., Bond, Samuel M., Calvo, Jennifer A., Doshi, Mihir B., Bere, Matt, Ou, Jianhong, Deng, Bin, Zhu, Lihua J., Johnson, Neil, Cantor, Sharon B. · 2021 · Cancer Research

Published version of a preprint

Abstract

Defects in DNA repair and the protection of stalled DNA replication forks are thought to underlie the chemosensitivity of tumors deficient in the hereditary breast cancer genes BRCA1 and BRCA2 (BRCA). Challenging this assumption are recent findings that indicate chemotherapies, such as cisplatin used to treat BRCA-deficient tumors, do not initially cause DNA double-strand breaks (DSB). Here, we show that ssDNA replication gaps underlie the hypersensitivity of BRCA-deficient cancer and that defects in homologous recombination (HR) or fork protection (FP) do not. In BRCA-deficient cells, ssDNA gaps developed because replication was not effectively restrained in response to stress. Gap suppression by either restoration of fork restraint or gap filling conferred therapy resistance in tissue culture and BRCA patient tumors. In contrast, restored FP and HR could be uncoupled from therapy resistance when gaps were present. Moreover, DSBs were not detected after therapy when apoptosis was inhibited, supporting a framework in which DSBs are not directly induced by genotoxic agents, but rather are induced from cell death nucleases and are not fundamental to the mechanism of action of genotoxic agents. Together, these data indicate that ssDNA replication gaps underlie the BRCA cancer phenotype, “BRCAness,” and we propose they are fundamental to the mechanism of action of genotoxic chemotherapies. Significance: This study suggests that ssDNA replication gaps are fundamental to the toxicity of genotoxic agents and underlie the BRCA-cancer phenotype “BRCAness,” yielding promising biomarkers, targets, and opportunities to resensitize refractory disease. See related commentary by Canman, p. 1214

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-20-1602

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Research works printed but not linked: 52

  1. King, 1986, Genetic analysis of human breast cancer: literature review and description of family data in workshop, Genet Epidemiol Suppl, 1, 3
  2. Munnell, 1968, The changing prognosis and treatment in cancer of the ovary. A report of 235 patients with primary ovarian carcinoma 1952–1961, Am J Obstet Gynecol, 100, 790, 10.1016/S0002-9378(15)33580-8 · doi:10.1016/s0002-9378(15)33580-8
  3. Li, 2008, Homologous recombination in DNA repair and DNA damage tolerance, Cell Res, 18, 99, 10.1038/cr.2008.1 · DOI · Paper page
  4. Feng, 2017, Homologous recombination and replication fork protection: BRCA2 and more!, Cold Spring Harb Symp Quant Biol, 82, 329, 10.1101/sqb.2017.82.035006 · DOI
  5. Lomonosov, 2003, Stabilization of stalled DNA replication forks by the BRCA2 breast cancer susceptibility protein, Genes Dev, 17, 3017, 10.1101/gad.279003 · DOI · Paper page
  6. Schlacher, 2011, Double-strand break repair-independent role for BRCA2 in blocking stalled replication fork degradation by MRE11, Cell, 145, 529, 10.1016/j.cell.2011.03.041 · DOI · Paper page
  7. Huang, 2013, The DNA translocase FANCM/MHF promotes replication traverse of DNA interstrand crosslinks, Mol Cell, 52, 434, 10.1016/j.molcel.2013.09.021 · DOI · Paper page
  8. Mutreja, 2018, ATR-mediated global fork slowing and reversal assist fork traverse and prevent chromosomal breakage at DNA interstrand cross-links, Cell Rep, 24, 2629, 10.1016/j.celrep.2018.08.019 · DOI
  9. Cantor, 2017, Fork protection and therapy resistance in hereditary breast cancer, Cold Spring Harb Symp Quant Biol, 82, 339, 10.1101/sqb.2017.82.034413 · DOI
  10. Bunting, 2012, BRCA1 functions independently of homologous recombination in DNA interstrand crosslink repair, Mol Cell, 46, 125, 10.1016/j.molcel.2012.02.015 · DOI · Paper page
  11. Wang, 2015, A dominant mutation in human RAD51 reveals its function in DNA interstrand crosslink repair independent of homologous recombination, Mol Cell, 59, 478, 10.1016/j.molcel.2015.07.009 · DOI · Paper page
  12. Barazas, 2019, Radiosensitivity is an acquired vulnerability of PARPi-resistant BRCA1-deficient tumors, Cancer Res, 79, 452, 10.1158/0008-5472.CAN-18-2077 · DOI
  13. Bruno, 2017, A subset of platinum-containing chemotherapeutic agents kills cells by inducing ribosome biogenesis stress, Nat Med, 23, 461, 10.1038/nm.4291 · DOI · Paper page
  14. Heijink, 2019, Modeling of cisplatin-induced signaling dynamics in triple-negative breast cancer cells reveals mediators of sensitivity, Cell Rep, 28, 2345, 10.1016/j.celrep.2019.07.070 · DOI
  15. Koc, 2004, Hydroxyurea arrests DNA replication by a mechanism that preserves basal dNTP pools, J Biol Chem, 279, 223, 10.1074/jbc.M303952200 · DOI · Paper page
  16. Ray Chaudhuri, 2016, Replication fork stability confers chemoresistance in BRCA-deficient cells, Nature, 535, 382, 10.1038/nature18325 · DOI · Paper page
  17. Sakai, 2009, Functional restoration of BRCA2 protein by secondary BRCA2 mutations in BRCA2-mutated ovarian carcinoma, Cancer Res, 69, 6381, 10.1158/0008-5472.CAN-09-1178 · DOI · Paper page
  18. Quinet, 2017, DNA fiber analysis: mind the gap!, Methods Enzymol, 591, 55, 10.1016/bs.mie.2017.03.019 · DOI · Paper page
  19. Guillemette, 2015, Resistance to therapy in BRCA2 mutant cells due to loss of the nucleosome remodeling factor CHD4, Genes Dev, 29, 489, 10.1101/gad.256214.114 · DOI
  20. O’Shaughnessy, 2013, CHD4 in the DNA-damage response and cell cycle progression: not so NuRDy now, Biochem Soc Trans, 41, 777, 10.1042/BST20130027 · DOI
  21. Rondinelli, 2017, EZH2 promotes degradation of stalled replication forks by recruiting MUS81 through histone H3 trimethylation, Nat Cell Biol, 19, 1371, 10.1038/ncb3626 · DOI · Paper page
  22. Meghani, 2018, Multifaceted impact of microRNA 493-5p on genome-stabilizing pathways induces platinum and PARP inhibitor resistance in BRCA2-mutated carcinomas, Cell Rep, 23, 100, 10.1016/j.celrep.2018.03.038 · DOI
  23. Mengwasser, 2019, Genetic screens reveal FEN1 and APEX2 as BRCA2 synthetic lethal targets, Mol Cell, 73, 885, 10.1016/j.molcel.2018.12.008 · DOI · Paper page
  24. Taglialatela, 2017, Restoration of replication fork stability in BRCA1- and BRCA2-deficient cells by inactivation of SNF2-family fork remodelers, Mol Cell, 68, 414, 10.1016/j.molcel.2017.09.036 · DOI · Paper page
  25. Kolinjivadi, 2017, Smarcal1-mediated fork reversal triggers Mre11-dependent degradation of nascent DNA in the absence of Brca2 and stable Rad51 nucleofilaments, Mol Cell, 67, 867, 10.1016/j.molcel.2017.07.001 · DOI · Paper page
  26. Bhat, 2018, RADX modulates RAD51 activity to control replication fork protection, Cell Rep, 24, 538, 10.1016/j.celrep.2018.06.061 · DOI
  27. Zellweger, 2015, Rad51-mediated replication fork reversal is a global response to genotoxic treatments in human cells, J Cell Biol, 208, 563, 10.1083/jcb.201406099 · DOI · Paper page
  28. Van Noorden, 2001, The history of Z-VAD-FMK, a tool for understanding the significance of caspase inhibition, Acta Histochem, 103, 241, 10.1078/0065-1281-00601 · DOI
  29. Henry-Mowatt, 2003, XRCC3 and Rad51 modulate replication fork progression on damaged vertebrate chromosomes, Mol Cell, 11, 1109, 10.1016/S1097-2765(03)00132-1 · DOI · Paper page
  30. Sugimura, 2008, PARP-1 ensures regulation of replication fork progression by homologous recombination on damaged DNA, J Cell Biol, 183, 1203, 10.1083/jcb.200806068 · DOI · Paper page
  31. Su, 2008, Cell-cycle coordination between DNA replication and recombination revealed by a vertebrate N-end rule degron-Rad51, Nat Struct Mol Biol, 15, 1049, 10.1038/nsmb.1490 · DOI
  32. Hashimoto, 2010, Rad51 protects nascent DNA from Mre11-dependent degradation and promotes continuous DNA synthesis, Nat Struct Mol Biol, 17, 1305, 10.1038/nsmb.1927 · DOI · Paper page
  33. Luke-Glaser, 2010, FANCM regulates DNA chain elongation and is stabilized by S-phase checkpoint signalling, EMBO J, 29, 795, 10.1038/emboj.2009.371 · DOI
  34. Vallerga, 2015, Rad51 recombinase prevents Mre11 nuclease-dependent degradation and excessive PrimPol-mediated elongation of nascent DNA after UV irradiation, Proc Natl Acad Sci U S A, 112, E6624, 10.1073/pnas.1508543112 · DOI
  35. Kolinjivadi, 2017, Moonlighting at replication forks - a new life for homologous recombination proteins BRCA1, BRCA2 and RAD51, FEBS Lett, 591, 1083, 10.1002/1873-3468.12556 · DOI
  36. Wong, 2020, Processing of DNA polymerase-blocking lesions during genome replication is spatially and temporally segregated from replication forks, Mol Cell, 77, 3, 10.1016/j.molcel.2019.09.015 · DOI
  37. Elvers, 2011, UV stalled replication forks restart by re-priming in human fibroblasts, Nucleic Acids Res, 39, 7049, 10.1093/nar/gkr420 · DOI
  38. Mourón, 2013, Repriming of DNA synthesis at stalled replication forks by human PrimPol, Nat Struct Mol Biol, 20, 1383, 10.1038/nsmb.2719 · DOI · Paper page
  39. Bianchi, 2013, PrimPol bypasses UV photoproducts during eukaryotic chromosomal DNA replication, Mol Cell, 52, 566, 10.1016/j.molcel.2013.10.035 · DOI · Paper page
  40. Xu, 2019, BRCA1 represses DNA replication initiation through antagonizing estrogen signaling and maintains genome stability in parallel with WEE1-MCM2 signaling during pregnancy, Hum Mol Genet, 28, 842, 10.1093/hmg/ddy398 · DOI
  41. Mijic, 2017, Replication fork reversal triggers fork degradation in BRCA2-defective cells, Nat Commun, 8, 859, 10.1038/s41467-017-01164-5 · DOI · Paper page
  42. Zimmermann, 2018, CRISPR screens identify genomic ribonucleotides as a source of PARP-trapping lesions, Nature, 559, 285, 10.1038/s41586-018-0291-z · DOI · Paper page
  43. Faivre, 2003, DNA strand breaks and apoptosis induced by oxaliplatin in cancer cells, Biochem Pharmacol, 66, 225, 10.1016/S0006-2952(03)00260-0 · DOI · Paper page
  44. Sane, 1998, Distinct steps in DNA fragmentation pathway during camptothecin-induced apoptosis involved caspase-, benzyloxycarbonyl- and N-tosyl-L-phenylalanylchloromethyl ketone-sensitive activities, Cancer Res, 58, 3066
  45. Nowosielska, 2005, Cisplatin induces DNA double-strand break formation in Escherichia coli dam mutants, DNA Repair, 4, 773, 10.1016/j.dnarep.2005.03.006 · DOI
  46. Kawane, 2014, DNA degradation and its defects, Cold Spring Harb Perspect Biol, 6, a016394, 10.1101/cshperspect.a016394 · DOI
  47. Sakahira, 1998, Cleavage of CAD inhibitor in CAD activation and DNA degradation during apoptosis, Nature, 391, 96, 10.1038/34214 · DOI · Paper page
  48. Huang, 1996, Sensitivity and selectivity of the DNA damage sensor responsible for activating p53-dependent G1 arrest, Proc Natl Acad Sci U S A, 93, 4827, 10.1073/pnas.93.10.4827 · DOI · Paper page
  49. Tidd, 2000, Oligodeoxynucleotide 5mers containing a 5′-CpG induce apoptosis through a mitochondrial mechanism in T lymphocytic leukaemia cells, Nucleic Acids Res, 28, 2242, 10.1093/nar/28.11.2242 · DOI
  50. Nayak, 2020, Inhibition of the translesion synthesis polymerase REV1 exploits replication gaps as a cancer vulnerability, Sci Adv, 6, eaaz7808, 10.1126/sciadv.aaz7808 · DOI
  51. Tonzi, 2019, Role of Y-family translesion DNA polymerases in replication stress: implications for new cancer therapeutic targets, DNA Repair, 78, 20, 10.1016/j.dnarep.2019.03.016 · DOI
  52. Cong, 2019, PARPi synthetic lethality derives from replication-associated single-stranded DNA gaps, bioRxiv, 781989

Cited by

See all 212

Metadata

Authors
Panzarino, N. J., Krais, J. J., Cong, K., Peng, M., Mosqueda, M., Nayak, S. U., Bond, S. M., Calvo, J. A., Doshi, M. B., Bere, M., Ou, J., Deng, B., Zhu, L. J., Johnson, N., & Cantor, S. B.
Venue
Cancer Research
Published
2021-03-01
Volume
81
Issue
5
Pages
1388-1397
ISSN
  • 0008-5472 (ISSN-L)
  • 1538-7445
OpenAlex
W3099886820
Cited by
212
References
7
FWCI
7.54
Type
journal article
Language
en
Open access
bronze
Funders
  • Foundation for the National Institutes of Health (R01 CA225018-02, R01 CA247232, R01 CA254037, R01 CA214799)
  • U.S. Department of Defense (OC130212)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Replication Gaps Underlie BRCA Deficiency and Therapy Response. https://app.cochat.ai/papers/10.1158/0008-5472.can-20-1602
The paper
Panzarino, N. J., Krais, J. J., Cong, K., Peng, M., Mosqueda, M., Nayak, S. U., Bond, S. M., Calvo, J. A., Doshi, M. B., Bere, M., Ou, J., Deng, B., Zhu, L. J., Johnson, N., & Cantor, S. B. (2021). Replication Gaps Underlie BRCA Deficiency and Therapy Response. Cancer Research. https://doi.org/10.1158/0008-5472.can-20-1602

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.